Business Context and Reporting Period
This Form 8-K was filed by Emergent BioSolutions Inc. on December 27, 2006, reporting events occurring on December 21 and December 22, 2006. The filing concerns Emergent BioDefense Operations Lansing Inc., a wholly owned subsidiary, and its financing arrangements with Fifth Third Bank.
Key Financial Metrics and Debt
- Debt Facility: A revolving line of credit of up to $10.0 million.
- Drawdown: On December 22, 2006, the subsidiary borrowed the full $10.0 million under the agreement.
- Maturity Date: February 15, 2007.
- Interest Rate: Prime rate minus 0.375%, payable monthly.
- Collateral: Secured by accounts receivable from U.S. Department of Defense and Department of Health and Human Services contracts for BioThrax.
- Borrowing Limit: Outstanding principal cannot exceed 75% of eligible accounts receivable (not older than 90 days).
- Liquidity/Covenants: The subsidiary must maintain a total liabilities to tangible net worth ratio of no more than 2.5 to 1.0.
Note: The filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes
The primary material change is the execution of a Fourth Amendment to the Amended and Restated Loan Agreement on December 21, 2006. This amendment renewed and extended the term of the loan facility to February 15, 2007. Subsequently, the subsidiary utilized the full capacity of the facility by borrowing $10.0 million on December 22, 2006.
Outlook, Risks, and Contingencies
Risks and Events of Default: The loan agreement includes specific events of default that could trigger acceleration of payment obligations, including:
- Payment defaults or failure to comply with covenants.
- Default on other indebtedness exceeding $500,000.
- Termination of Government Contracts or failure to perform obligations under them.
- Court or governmental orders preventing the sale of BioThrax.
- Bankruptcy or insolvency.
Covenants: Negative covenants restrict the subsidiary's ability to incur additional indebtedness, sell assets, make loans, enter into mergers, or amend Government Contracts without consent.
Investor Verification Checklist
- Verify the current status of the $10.0 million loan and whether it was repaid prior to the February 15, 2007 maturity.
- Confirm the volume and age of eligible accounts receivable from Government Contracts to ensure the 75% borrowing limit was sustainable.
- Review the subsidiary's financial statements to confirm compliance with the 2.5 to 1.0 liabilities-to-tangible-net-worth covenant.
- Monitor the status of BioThrax supply contracts with the U.S. Department of Defense and HHS for any termination risks.